Momenta

Investor Relations

NASDAQ: MNTA
Price
11.00
Change
+ 0.05
Day High
11.15
Day Low
10.91
Volume
24,100
10:05 AM ET on Oct 30, 2014
Stock price graph

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

In July 2010, the Momenta’s lead product (developed in collaboration with Sandoz) was approved as the first generic version of Lovenox® (Enoxaparin Sodium Injection).  The company’s development pipeline includes a generic version of Copaxone® (glatiramer acetate), also in collaboration with Sandoz, biosimilars in collaboration with Baxter.    necuparanib (formerly M402), a novel oncology drug candidate currently undergoing testing in early phase human clinical trials, and a portfolio of novel autoimmune drug candidates.

View Annual Report and Proxy Material

View all »   RSSRecent Releases

Oct 22, 2014
Momenta Pharmaceuticals Announces Date of Third Quarter 2014 Financial Results Conference Call and Webcast

Oct 9, 2014
Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer

Oct 2, 2014
Momenta Pharmaceuticals to Host 2014 R&D Day

View all »Events & Presentations

Nov 5, 2014 at 10:00 AM ET
Momenta Pharmaceuticals Third Quarter 2014 Earnings Call

Last Revised 6/12/2012